| Delaware                        |   | 62-1117144          |
|---------------------------------|--------|---------------------|
| (State or Other Jurisdiction of |   | (I.R.S. Employer    |
| Incorporation or Organization)  |   | Identification No.) |

| 701 Cool Springs Boulevard, Franklin, TN  37067 |
|-----------------------------------------------------------|
| (Address of Principal Executive Offices) (Zip Code)       |

| 615-614-4929                                               |
|------------------------------------------------------------|
| (Registrant’s Telephone Number, Including Area Code) |

|                                                                               |
|------------------------------------------------------------------------------------|
| (Former name, former address and former fiscal year, if changed since last report) |

----

| Non-accelerated filer ¨ | (Do not check if a smaller reporting company) | Smaller reporting company ¨ |
|------------------------------|-----------------------------------------------|----------------------------------|

----

|   |    |     |                                                                                       | Page     |   |
|--------|---------|----------|--------------------------------------------------------------------------------------------|----------|--------|
|   | Part I  |     |                                                                                       |     |   |
|   |    | Item 1.  | Financial Statements                                                                       | 4        |   |
|   |    | Item 2.  | Management’s Discussion and Analysis of Financial Condition andResults of Operations |  18 |   |
|   |    | Item 3.  | Quantitative and Qualitative Disclosures About Market Risk                                 | 30       |   |
|   |    | Item 4.  | Controls and Procedures                                                                    | 31       |   |
|   | Part II |     |                                                                                       |     |   |
|   |    | Item 1.  | Legal Proceedings                                                                          | 32       |   |
|   |    | Item 1A. | Risk Factors                                                                               | 33       |   |
|   |    | Item 2.  | Unregistered Sales of Equity Securities and Use of Proceeds                                | 34       |   |
|   |    | Item 3.  | Defaults Upon Senior Securities                                                            | 34       |   |
|   |    | Item 4.  | Removed and Reserved                                                                       | 34       |   |
|   |    | Item 5.  | Other Information                                                                          | 34       |   |
|   |    | Item 6.  | Exhibits                                                                                   | 34       |   |

----

| Item 1. | Financial Statements |   |
|---------|----------------------|--------|

|   |                                                             |   | March 31, |     |   |   | December 31, |   |     |   |
|--------|------------------------------------------------------------------|--------|-----------|----------|--------|--------|--------------|--------|----------|--------|
|   |                                                             |   | 2011      |     |   |   | 2010         |   |     |   |
|   | Current assets:                                                  |   |      |     |   |   |         |   |     |   |   |
|   | Cash and cash equivalents                                        |   | $         | 4,336    |   |   |         | $      | 1,064    |   |   |
|   | Accounts receivable, net                                         |   |      | 87,261   |   |   |         |   | 89,108   |   |   |
|   | Prepaid expenses                                                 |   |      | 9,387    |   |   |         |   | 12,577   |   |   |
|   | Other current assets                                             |   |      | 2,694    |   |   |         |   | 3,064    |   |   |
|   | Income taxes receivable                                          |   |      | 4,100    |   |   |         |   | 8,695    |   |   |
|   | Deferred tax asset                                               |   |      | 11,625   |   |   |         |   | 11,272   |   |   |
|   |   Total current assets                                 |   |      | 119,403  |   |   |         |   | 125,780  |   |   |
|   |                                                             |   |      |     |   |   |         |   |     |   |   |
|   | Property and equipment:                                          |   |      |     |   |   |         |   |     |   |   |
|   | Leasehold improvements                                           |   |      | 40,775   |   |   |         |   | 40,662   |   |   |
|   | Computer equipment and related software                          |   |      | 214,511  |   |   |         |   | 207,077  |   |   |
|   | Furniture and office equipment                                   |   |      | 27,443   |   |   |         |   | 27,328   |   |   |
|   | Capital projects in process                                      |   |      | 10,116   |   |   |         |   | 10,117   |   |   |
|   |                                                             |   |      | 292,845  |   |   |         |   | 285,184  |   |   |
|   | Less accumulated depreciation                                    |   |      | (163,767 | )      |   |         |   | (154,528 | )      |   |
|   |                                                             |   |      | 129,078  |   |   |         |   | 130,656  |   |   |
|   |                                                             |   |      |     |   |   |         |   |     |   |   |
|   | Other assets                                                     |   |      | 13,684   |   |   |         |   | 14,733   |   |   |
|   |                                                             |   |      |     |   |   |         |   |     |   |   |
|   | Intangible assets, net                                           |   |      | 92,836   |   |   |         |   | 94,255   |   |   |
|   | Goodwill, net                                                    |   |      | 496,265  |   |   |         |   | 496,265  |   |   |
|   |                                                             |   |      |     |   |   |         |   |     |   |   |
|   | Total assets                                                     |   | $         | 851,266  |   |   |         | $      | 861,689  |   |   |
|   |                                                             |   |      |     |   |   |         |   |     |   |   |
|   | See accompanying notes to the consolidated financial statements. |   |      |     |   |   |         |   |     |   |   |

----

|   |                                                                                         |   | March 31,     |   |   |   | December 31,  |   |
|--------|----------------------------------------------------------------------------------------------|--------|---------------|--------|--------|--------|---------------|--------|
|   |                                                                                         |   | 2011          |   |   |   | 2010          |   |
|   | Current liabilities:                                                                         |   |          |   |   |   |          |   |
|   | Accounts payable                                                                             | $      | 16,297        |   |   | $      | 22,555        |   |
|   | Accrued salaries and benefits                                                                |   | 34,851        |   |   |   | 39,157        |   |
|   | Accrued liabilities                                                                          |   | 36,108        |   |   |   | 31,532        |   |
|   | Deferred revenue                                                                             |   | 5,568         |   |   |   | 5,931         |   |
|   | Contract billings in excess of earned revenue                                                |   | 20,617        |   |   |   | 18,814        |   |
|   | Current portion of long-term debt                                                            |   | 2,999         |   |   |   | 3,935         |   |
|   | Current portion of long-term liabilities                                                     |   | 3,759         |   |   |   | 3,309         |   |
|   | Total current liabilities                                                                    |   | 120,199       |   |   |   | 125,233       |   |
|   |                                                                                         |   |          |   |   |   |          |   |
|   | Long-term debt                                                                               |   | 239,625       |   |   |   | 243,425       |   |
|   | Long-term deferred tax liability                                                             |   | 22,354        |   |   |   | 23,050        |   |
|   | Other long-term liabilities                                                                  |   | 33,942        |   |   |   | 39,140        |   |
|   |                                                                                         |   |          |   |   |   |          |   |
|   | Stockholders’ equity:                                                                  |   |          |   |   |   |          |   |
|   | Preferred stock                                                                              |   |          |   |   |   |          |   |
|   |       $.001 par value, 5,000,000 shares                        |   |          |   |   |   |          |   |
|   | authorized, none outstanding                                                                 |   |  — |   |   |   |  — |   |
|   | Common stock                                                                                 |   |          |   |   |   |          |   |
|   |       $.001 par value, 120,000,000 shares authorized,          |   |          |   |   |   |          |   |
|   |         33,987,051 and 34,018,706 shares outstanding |   | 34            |   |   |   | 34            |   |
|   | Additional paid-in capital                                                                   |   | 235,864       |   |   |   | 232,524       |   |
|   | Retained earnings                                                                            |   | 210,345       |   |   |   | 206,210       |   |
|   | Treasury stock, at cost, 728,547 and 429,654 shares in treasury                              |   | (8,362        | )      |   |   | (4,494        | )      |
|   | Accumulated other comprehensive loss                                                         |   | (2,735        | )      |   |   | (3,433        | )      |
|   |   Total stockholders’ equity                                                 |   | 435,146       |   |   |   | 430,841       |   |
|   |                                                                                         |   |          |   |   |   |          |   |
|   | Total liabilities and stockholders’ equity                                             | $      | 851,266       |   |   | $      | 861,689       |   |
|   |                                                                                         |   |          |   |   |   |          |   |

|   | See accompanying notes to the consolidated financial statements. |   |
|--------|------------------------------------------------------------------|--------|

----

|   |                                                                                                              |   |   | Three Months Ended |   |   |
|--------|-------------------------------------------------------------------------------------------------------------------|--------|--------|--------------------|--------|--------|
|   |                                                                                                              |   |   | March 31,          |   |   |
|   |                                                                                                              |   | 2011   |               |   | 2010   |   |   |
|   |                                                                                                              |   |   |               |   |   |   |   |   |   |
|   | Revenues                                                                                                          |   | $      | 162,969            |   |   | $ | 178,999 |   |   |
|   | Cost of services (exclusive of depreciation and amortization of $9,023 and $10,233, respectively, included below) |   |   | 121,908            |   |   |   | 128,868 |   |   |
|   | Selling, general & administrative expenses                                                                    |   |   | 17,842             |   |   |   | 17,235 |   |   |
|   | Depreciation and amortization                                                                                     |   |   | 12,433             |   |   |   | 13,554 |   |   |
|   |                                                                                                              |   |   |               |   |   |   |   |   |   |
|   | Operating income                                                                                                  |   |   | 10,786             |   |   |   | 19,342 |   |   |
|   |  Interest expense                                                                                            |   |   | 3,418              |   |   |   | 3,422 |   |   |
|   |                                                                                                              |   |   |               |   |   |   |   |   |   |
|   | Income before income taxes                                                                                        |   |   | 7,368              |   |   |   | 15,920 |   |   |
|   | Income tax expense                                                                                                |   |   | 3,233              |   |   |   | 6,506 |   |   |
|   |                                                                                                              |   |   |               |   |   |   |   |   |   |
|   | Net income                                                                                                        |   | $      | 4,135              |   |   | $ | 9,414 |   |   |
|   |                                                                                                              |   |   |               |   |   |   |   |   |   |
|   | Earnings per share:                                                                                               |   |   |               |   |   |   |   |   |   |
|   |   Basic                                                                                                 |   | $      | 0.12               |   |   | $ | 0.28 |   |   |
|   |                                                                                                              |   |   |               |   |   |   |   |   |   |
|   |   Diluted                                                                                               |   | $      | 0.12               |   |   | $ | 0.27 |   |   |
|   |                                                                                                              |   |   |               |   |   |   |   |   |   |
|   | Weighted average common shares                                                                                    |   |   |               |   |   |   |   |   |   |
|   | and equivalents:                                                                                                  |   |   |               |   |   |   |   |   |   |
|   | Basic                                                                                                             |   |   | 33,975             |   |   |   | 33,955 |   |   |
|   | Diluted                                                                                                           |   |   | 34,690             |   |   |   | 34,919 |   |   |
|   |                                                                                                              |   |   |               |   |   |   |   |   |   |

|   | See accompanying notes to the consolidated financial statements. |   |
|--------|------------------------------------------------------------------|--------|

----

|                                                                                |   |      |          |   |   |          |   |     |          |     |   | Accumulated         |   |   |    |
|-------------------------------------------------------------------------------------|--------|-----------|---------------|--------|--------|---------------|--------|----------|---------------|----------|--------|---------------------|--------|--------|---------|
|                                                                                |   |      |          |   |   | Additional    |   |     |          |     |   | Other               |   |   |    |
|                                                                                |   | Preferred |          | Common |   | Paid-in       |   | Retained |          | Treasury |   | Comprehensive       |   |   |    |
|                                                                                |   | Stock     |          | Stock  |   | Capital       |   | Earnings |          | Stock    |   | Income (Loss)       |   | Total  |    |
| Balance, December 31, 2010                                                          |   |      | $—      |   |   | $34      |   |     | $232,524      |     |   | $206,210            |   |   | $(4,494 | ) |   |  $(3,433 | ) | $430,841 |   |   |
|                                                                                |   |      |          |   |   |          |   |     |          |     |   |                |   |   |    |   |   |   |   |   |   |   |
| Comprehensive income:                                                               |   |      |          |   |   |          |   |     |          |     |   |                |   |   |    |   |   |   |   |   |   |   |
|                                                                                |   |      |          |   |   |          |   |     |          |     |   |                |   |   |    |   |   |   |   |   |   |   |
| Net income                                                                          |   |      |  — |   |   |  — |   |     |  — |     |   | 4,135               |   |   | — |   |   |  — |   | 4,135 |   |   |
|                                                                                |   |      |          |   |   |          |   |     |          |     |   |                |   |   |    |   |   |   |   |   |   |   |
| Net change in fair value of interest rate                                           |   |      |          |   |   |          |   |     |          |     |   |                |   |   |    |   |   |   |   |   |   |   |
| swaps, net of income tax expense of $508                                            |   |      |  — |   |   |  — |   |     |  — |     |   |  —       |   |   | — |   |   | 786 |   | 786 |   |   |
|                                                                                |   |      |          |   |   |          |   |     |          |     |   |                |   |   |    |   |   |   |   |   |   |   |
| Foreign currency translation adjustment                                             |   |      |  — |   |   |  — |   |     |  — |     |   | —             |   |   | — |   |   | (88 | ) | (88 | ) |   |
|                                                                                |   |      |          |   |   |          |   |     |          |     |   |                |   |   |    |   |   |   |   |   |   |   |
| Total comprehensive income                                                          |   |      |          |   |   |          |   |     |          |     |   |                |   |   |    |   |   |   |   | 4,833 |   |   |
|                                                                                |   |      |          |   |   |          |   |     |          |     |   |                |   |   |    |   |   |   |   |   |   |   |
| Repurchases of common stock                                                         |   |      | —       |   |   | —       |   |     | —       |     |   | —             |   |   | (3,868  | ) |   | — |   | (3,868 | ) |   |
|                                                                                |   |      |          |   |   |          |   |     |          |     |   |                |   |   |    |   |   |   |   |   |   |   |
| Exercise of stock options and other                                                 |   |      |  — |   |   | —       |   |     | 1,885         |     |   |  —       |   |   | — |   |   |  —  |   | 1,885 |   |   |
|                                                                                |   |      |          |   |   |          |   |     |          |     |   |                |   |   |    |   |   |   |   |   |   |   |
| Tax effect of stock options and restricted     stock units |   |      |  — |   |   |  — |   |     | (797          | )        |   |  —  |   |   | — |   |   |  —  |   | (797 | ) |   |
|                                                                                |   |      |          |   |   |          |   |     |          |     |   |                |   |   |    |   |   |   |   |   |   |   |
| Share-based employee compensation expense                                           |   |      |  — |   |   |  — |   |     | 2,252         |     |   |  —  |   |   | — |   |   |  —  |   | 2,252 |   |   |
|                                                                                |   |      |          |   |   |          |   |     |          |     |   |                |   |   |    |   |   |   |   |   |   |   |
| Balance, March 31, 2011                                                             |   |      | $—      |   |   | $34      |   |     | $235,864      |     |   | $210,345            |   |   | $(8,362 | ) |   |  $(2,735 | ) | $435,146 |   |   |

| See accompanying notes to the consolidated financial statements. |
|------------------------------------------------------------------|

----

|                                                                   |                                                          |   | Three Months Ended |     |
|------------------------------------------------------------------------|---------------------------------------------------------------|--------|--------------------|----------|
|                                                                   |                                                          |   | March 31,          |     |
|                                                                   |                                                          |   | 2011               |     |   |   | 2010 |   |
|                                                                   | Cash flows from operating activities:                         |   |               |     |   |   |   |   |   |   |
|                                                                   | Net income                                                    |   | $                  | 4,135    |   |   |   | $ | 9,414 |   |
|                                                                   | Adjustments to reconcile net income to net cash provided by   |   |               |     |   |   |   |   |   |   |
|                                                                   | (used in) operating activities, net of business acquisitions: |   |               |     |   |   |   |   |   |   |
|                                                                   | Depreciation and amortization                                 |   |               | 12,433   |   |   |   |   | 13,554 |   |
|                                                                   | Amortization of deferred loan costs                           |   |               | 477      |   |   |   |   | 396 |   |
|                                                                   | Share-based employee compensation expense                     |   |               | 2,252    |   |   |   |   | 2,972 |   |
|                                                                   | Excess tax benefits from share-based payment arrangements     |   |               | (172     | ) |   |   |   | (401 | ) |
|                                                                   | Decrease (increase) in accounts receivable, net               |   |               | 1,909    |   |   |   |   | (16,274 | ) |
|                                                                   | Decrease in other current assets                              |   |               | 7,022    |   |   |   |   | 2,853 |   |
|                                                                   | Decrease in accounts payable                                  |   |               | (2,782   | ) |   |   |   | (6,744 | ) |
|                                                                   | Decrease in accrued salaries and benefits                     |   |               | (10,248  | ) |   |   |   | (25,322 | ) |
|                                                                   | Increase in other current liabilities                         |   |               | 7,805    |   |   |   |   | 10,225 |   |
|                                                                   | Deferred income taxes                                         |   |               | (2,700   | ) |   |   |   | 3,509 |   |
|                                                                   | Other                                                         |   |               | 928      |   |   |   |   | 1,892 |   |
|                                                                   | Decrease (increase) in other assets                           |   |               | 137      |   |   |   |   | (1,034 | ) |
|                                                                   | Payments on other long-term liabilities                       |   |               | (358     | ) |   |   |   | (2,313 | ) |
|                                                                   | Net cash flows provided by (used in) operating activities     |   |               | 20,838   |   |   |   |   | (7,273 | ) |
|                                                                   |                                                          |   |               |     |   |   |   |   |   |   |
|                                                                   | Cash flows from investing activities:                         |   |               |     |   |   |   |   |   |   |
|                                                                   | Change in restricted cash                                     |   |               | 469      |   |   |   |   | — |   |
|                                                                   | Acquisition of property and equipment                         |   |               | (9,787   | ) |   |   |   | (12,638 | ) |
|                                                                   | Other                                                         |   |               | (1,796   | ) |   |   |   | (1,412 | ) |
|                                                                   | Net cash flows used in investing activities                   |   |               | (11,114  | ) |   |   |   | (14,050 | ) |
|                                                                   |                                                          |   |               |     |   |   |   |   |   |   |
|                                                                   | Cash flows from financing activities:                         |   |               |     |   |   |   |   |   |   |
|                                                                   | Proceeds from issuance of long-term debt                      |   |               | 119,918  |   |   |   |   | 281,250 |   |
|                                                                   | Payments of long-term debt                                    |   |               | (123,445 | ) |   |   |   | (256,922 | ) |
|                                                                   | Deferred loan costs                                           |   |               | (40      | ) |   |   |   | (2,963 | ) |
|                                                                   | Excess tax benefits from share-based payment arrangements     |   |               | 172      |   |   |   |   | 401 |   |
|                                                                   | Exercise of stock options                                     |   |               | 1,862    |   |   |   |   | 393 |   |
|                                                                   | Repurchases of common stock                                   |   |               | (3,868   | ) |   |   |   | — |   |
|                                                                   | Change in outstanding checks and other                        |   |               | (1,320   | ) |   |   |   | (1,817 | ) |
|                                                                   | Net cash flows (used in) provided by financing activities     |   |               | (6,721   | ) |   |   |   | 20,342 |   |
|                                                                   |                                                          |   |               |     |   |   |   |   |   |   |
|                                                                   | Effect of exchange rate changes on cash                       |   |               | 269      |   |   |   |   | (86 | ) |
|                                                                   |                                                          |   |               |     |   |   |   |   |   |   |
|                                                                   | Net increase (decrease) in cash and cash equivalents          |   |               | 3,272    |   |   |   |   | (1,067 | ) |
|                                                                   |                                                          |   |               |     |   |   |   |   |   |   |
|                                                                   | Cash and cash equivalents, beginning of period                |   |               | 1,064    |   |   |   |   | 2,356 |   |
|                                                                   |                                                          |   |               |     |   |   |   |   |   |   |
|                                                                   | Cash and cash equivalents, end of period                      |   | $                  | 4,336    |   |   |   | $ | 1,289 |   |
|  See accompanying notes to the consolidated financial statements. |                                                          |   |

----

| (1) | Basis of Presentation |   |
|-----|-----------------------|--------|

| (2) | Share-Based Compensation |   |
|-----|--------------------------|--------|

|   |                           |   |   |   |           |   | Weighted-    |   |   |          |    |   |
|--------|--------------------------------|--------|--------|--------|----------------|--------|--------------|--------|--------|---------------|---------|--------|
|   |                           |   |   |   |           |   | Average      |   |   |          |    |   |
|   |                           |   |   |   | Weighted-      |   | Remaining    |   |   | Aggregate     |    |   |
|   |                           |   | Shares |   | Average        |   | Contractual  |   |   | Intrinsic     |    |   |
|   | Options                        |   | (000s) |   | Exercise Price |   | Term (years) |   |   | Value ($000s) |    |   |
|   | Outstanding at January 1, 2011 |   | 6,208  |   | $              | 17.12  |         |   |   |          |    |   |   |
|   | Granted                        |   | 259    |   |           | 14.16  |         |   |   |          |    |   |   |
|   | Exercised                      |   | (157   | )      |           | 11.44  |         |   |   |          |    |   |   |
|   | Forfeited or expired           |   | (50    | )      |           | 18.10  |         |   |   |          |    |   |   |
|   | Outstanding at March 31, 2011  |   | 6,260  |   |           | 17.14  |         | 5.48   |   |          | $16,440 |   |   |
|   | Exercisable at March 31, 2011  |   | 3,760  |   |           | 19.26  |         | 3.42   |   |          | 8,483   |   |   |

----

|   |                         |   |   |   |   | Weighted-  |   |
|--------|------------------------------|--------|--------|--------|--------|------------|--------|
|   |                         |   |   |   |   | Average    |   |
|   |                         |   | Shares |   |   | Grant Date |   |
|   | Nonvested Shares             |   | (000s) |   |   | Fair Value |   |
|   | Nonvested at January 1, 2011 |   | 1,153  |   |   | $          | 15.29  |   |
|   | Granted                      |   | 126    |   |   |       | 14.16  |   |
|   | Vested                       |   | (156   | )      |   |       | 14.45  |   |
|   | Forfeited                    |   | (16    | )      |   |       | 15.90  |   |
|   | Nonvested at March 31, 2011  |   | 1,107  |   |   |       | 15.28  |   |

| (3) | Income Taxes |   |
|-----|--------------|--------|

| (4) | Derivative Investments and Hedging Activities |   |
|-----|-----------------------------------------------|--------|

----

|   |                                                           |   | March 31, 2011                      |                          | December 31, 2010 |                                |                          |
|--------|----------------------------------------------------------------|--------|-------------------------------------|-------------------------------|-------------------|-------------------------------------|-------------------------------|
|   | (In $000s)                                                     |   | Foreign currency exchange contracts | Interest rate swap agreements |              | Foreign currency exchange contracts | Interest rate swap agreements |   |   |
|   | Assets:                                                        |   |                                |                          |              |                                |                          |   |   |
|   |                                                           |   |                                |                          |              |                                |                          |   |   |
|   |   Derivatives not designated as hedging instruments: |   |                                |                          |              |                                |                          |   |   |
|   |      Other current assets             |   | $56                                 | $—                      |              | $136                                | $—                      |   |   |
|   |                                                           |   |                                |                          |              |                                |                          |   |   |
|   |   Derivatives designated as hedging instruments:     |   |                                |                          |              |                                |                          |   |   |
|   |      Other assets                     |   | —                             | 25                            |              | —                             | —                       |   |   |
|   | Total assets                                                   |   | $56                                 | $25                           |              | $136                                | $—                      |   |   |
|   |                                                           |   |                                |                          |              |                                |                          |   |   |
|   |  Liabilities:                                             |   |                                |                          |              |                                |                          |   |   |
|   |   Derivatives not designated as hedging instruments: |   |                                |                          |              |                                |                          |   |   |
|   |      Accrued liabilities              |   | $192                                | $—                      |              | $245                                | $—                      |   |   |
|   |                                                           |   |                                |                          |              |                                |                          |   |   |
|   |   Derivatives designated as hedging instruments:     |   |                                |                          |              |                                |                          |   |   |
|   |      Accrued liabilities              |   | —                             | 3,261                         |              | —                             | 4,465                         |   |   |
|   |      Other long-term liabilities      |   | —                             | 2,528                         |              | —                             | 2,593                         |   |   |
|   | Total liabilities                                              |   | $192                                | $5,789                        |              | $245                                | $7,058                        |   |   |
|   |                                                           |   |                                |                          |              |                                |                          |   |   |

----

|   |                                               |   |   |   | Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)For the Three Months Ended |   |           |   |   |
|--------|----------------------------------------------------|--------|--------|--------|------------------------------------------------------------------------------------------------------|--------|----------------|--------|--------|
|   | Derivatives in Cash Flow Hedging Relationships     |   |   |   | March 31, 2011                                                                                       |   | March 31, 2010 |   |   |   |   |
|   | Interest rate swap agreements, gross of tax effect |   |   |   | $1,294                                                                                               |   | $(642)         |   |   |   |   |

| (5) | Fair Value Measurements |   |
|-----|-------------------------|--------|

|   |  Level 1:  Quoted prices in active markets for identical assets or liabilities;                                                                                                                                                                                                                                                                                                  |   |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
|   |  Level 2:  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-based valuation techniques in which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and |   |
|   |  Level 3:  Unobservable inputs that are supported by little or no market activity and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability.                                                                                                                                                        |   |

----

|   | (In 000s)March 31, 2011             |   |   |    Level 2 |   |   |  Gross Fair Value |   |   |    Netting (1) |   |   |   Net Fair Value |   |   |   |
|--------|-------------------------------------|--------|--------|---------------------------|--------|--------|------------------------|--------|--------|-------------------------------|--------|--------|----------------------------|--------|--------|--------|
|   | Assets:                             |   |   |                      |   |   |                   |   |   |                          |   |   |                       |   |   |   |
|   | Foreign currency exchange contracts |   | $      | 56                        |   | $      | 56                     |   | $      | (50                           | )      | $      | 6                          |   |   |   |
|   | Interest rate swap agreements       |   |   | 25                        |   | $      | 25                     |   |   | (25                           | )      |   | —                    |   |   |   |
|   | Liabilities:                        |   |   |                      |   |   |                   |   |   |                          |   |   |                       |   |   |   |
|   | Foreign currency exchange contracts |   | $      | 192                       |   | $      | 192                    |   | $      | (50                           | )      | $      | 142                        |   |   |   |
|   | Interest rate swap agreements       |   |   | 5,789                     |   |   | 5,789                  |   |   | (25                           | )      |   | 5,764                      |   |   |   |

|   | (In 000s)December 31, 2010          |   |   |    Level 2 |   |   |  Gross Fair Value |   |   |    Netting (1) |   |   |   Net Fair Value |   |   |   |
|--------|-------------------------------------|--------|--------|---------------------------|--------|--------|------------------------|--------|--------|-------------------------------|--------|--------|----------------------------|--------|--------|--------|
|   | Assets:                             |   |   |                      |   |   |                   |   |   |                          |   |   |                       |   |   |   |
|   | Foreign currency exchange contracts |   | $      | 136                       |   | $      | 136                    |   | $      | (116                          | )      | $      | 20                         |   |   |   |
|   | Liabilities:                        |   |   |                      |   |   |                   |   |   |                          |   |   |                       |   |   |   |
|   | Foreign currency exchange contracts |   | $      | 245                       |   | $      | 245                    |   | $      | (116                          | )      | $      | 129                        |   |   |   |
|   | Interest rate swap agreements       |   |   | 7,058                     |   |   | 7,058                  |   |   | —                       |   |   | 7,058                      |   |   |   |

|   | · | Cash and cash equivalents – The carrying amount of $4.3 million approximates fair value because of the short maturity of those instruments (less than three months). |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Long-term debt –The estimated fair value of outstanding borrowings under our credit agreement is based on the average of the prices set by the issuing bank given current market conditions and is not necessarily indicative of the amount we could realize in a current market exchange. The estimated fair value and carrying amount of outstanding borrowings under the Fourth Amended Credit Agreement (see Note 6) at March 31, 2011 are $227.7 million and $238.7 million, respectively. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (6) | Long-Term Debt |   |
|-----|----------------|--------|

| (7) | Restructuring and Related Charges and Impairment Loss |   |
|-----|-------------------------------------------------------|--------|

----

|   | (In 000s)                                                    |   |    |   |   |
|--------|--------------------------------------------------------------|--------|---------|--------|--------|
|   |                                                         |   |    |   |   |
|   | Accrued restructuring and related charges at January 1, 2011 | $      | 7,607   |   |   |
|   | Additions                                                    |   | — |   |   |
|   | Payments                                                     |   | (1,615  | )      |   |
|   | Adjustments                                                  |   | (234    | )      |   |
|   | Accrued restructuring and related charges at March 31, 2011  | $      | 5,758   |   |   |
|   |                                                         |   |    |   |   |

| (8) | Commitments and Contingencies |   |
|-----|-------------------------------|--------|

----

| (9) | Share Repurchases |   |
|-----|-------------------|--------|

----

| Period                |   |   | Total Number of Shares Purchased |   |   |   | Average Price Paid per Share |   |   |   | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1) |          |   |   | Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (1) |   |
|-----------------------|--------|--------|----------------------------------|--------|--------|--------|------------------------------|--------|--------|--------|--------------------------------------------------------------------------------------|---------------|--------|--------|------------------------------------------------------------------------------------------------------|--------|
|                  |   |   |                             |   |   |   |                         |   |   |   |                                                                                 |          |   |   |                                                                                                 |   |   |   |
| January 1 through 31  |   |   | 137,600                          |   |   |   |                         | $11.03 |   |   |                                                                                 |  567,254 |   |   |                                                                                                 |   | $53,987,364 |   |
| February 1 through 28 |   |   | 16,000                           |   |   |   |                         | $11.89 |   |   |                                                                                 | 583,254       |   |   |                                                                                                 |   | $53,797,124 |   |
| March 1 through 31    |   |   | 145,293                          |   |   |   |                         | $14.87 |   |   |                                                                                 | 728,547       |   |   |                                                                                                 |   | $51,636,617 |   |
|                  |   |   |                             |   |   |   |                         |   |   |   |                                                                                 |          |   |   |                                                                                                 |   |   |   |
| Total                 |   |   | 298,893                          |   |   |   |                         |   |   |   |                                                                                 |          |   |   |                                                                                                 |   |   |   |

| (10) | Comprehensive Income |   |
|------|----------------------|--------|

| (11) | Earnings Per Share |   |
|------|--------------------|--------|

|   | (In 000s, except per share data)                                                                                            |   | Three Months EndedMarch 31, |   |   |   |   |
|--------|-----------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------|--------|--------|--------|--------|
|   |                                                                                                                        |   | 2011                        |   | 2010   |   |   |   |
|   | Numerator:                                                                                                                  |   |                        |   |   |   |   |   |   |   |
|   | Net income - numerator for basic earnings per share                                                                         |   | $                           | 4,135  |   | $      | 9,414  |   |   |   |
|   |                                                                                                                        |   |                        |   |   |   |   |   |   |   |
|   | Denominator:                                                                                                                |   |                        |   |   |   |   |   |   |   |
|   | Shares used for basic earnings per share                                                                                    |   |                        | 33,975 |   |   | 33,955 |   |   |   |
|   | Effect of dilutive securities outstanding:                                                                                  |   |                        |   |   |   |   |   |   |   |
|   | Non-qualified stock options                                                                                                 |   |                        | 380    |   |   | 529    |   |   |   |
|   | Restricted stock units                                                                                                      |   |                        | 335    |   |   | 435    |   |   |   |
|   | Shares used for diluted earnings per share                                                                                  |   |                        | 34,690 |   |   | 34,919 |   |   |   |
|   |                                                                                                                        |   |                        |   |   |   |   |   |   |   |
|   | Earnings per share:                                                                                                         |   |                        |   |   |   |   |   |   |   |
|   | Basic                                                                                                                       |   | $                           | 0.12   |   | $      | 0.28   |   |   |   |
|   | Diluted                                                                                                                     |   | $                           | 0.12   |   | $      | 0.27   |   |   |   |
|   |                                                                                                                        |   |                        |   |   |   |   |   |   |   |
|   | Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive: |   |                        |   |   |   |   |   |   |   |
|   |  Non-qualified stock options                                                                                           |   |                        | 4,441  |   |   | 3,370  |   |   |   |
|   |         Restricted stock units                                                           |   |                        | 128    |   |   | 5      |   |   |   |

----

| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations |   |
|---------|---------------------------------------------------------------------------------------------|--------|

|   | · | fostering wellness and disease prevention through total population screening, well-being assessments and supportive interventions; and |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------|

|   | · | providing access to health improvement programs, such as fitness solutions, weight management, and complementary and alternative medicine. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | promoting the change and improvement of the lifestyle behaviors that lead to poor health or chronic conditions; and |
|--------|--------|---------------------------------------------------------------------------------------------------------------------|

|   | · | providing educational materials and personal interactions with highly trained nurses and other healthcare professionals to create and sustain healthier behaviors for those individuals at-risk or in the early stages of chronic conditions. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | incorporating the latest, evidence-based clinical guidelines into interventions to optimize patient health outcomes; |
|--------|--------|----------------------------------------------------------------------------------------------------------------------|

|   | · | developing care support plans and motivating members to set attainable goals for themselves; |
|--------|--------|----------------------------------------------------------------------------------------------|

|   | · | providing local market resources to address acute episodic interventions; |
|--------|--------|---------------------------------------------------------------------------|

|   | · | coordinating members’ care with their healthcare providers; |
|--------|--------|-------------------------------------------------------------------|

|   | · | providing software licensing and management consulting in support of well-being improvement services; and |
|--------|--------|-----------------------------------------------------------------------------------------------------------|

|   | · | providing high-risk care management for members at risk for hospitalization due to complex conditions. |
|--------|--------|--------------------------------------------------------------------------------------------------------|

|   | · | our ability to sign and implement new contracts for our solutions; |
|--------|--------|--------------------------------------------------------------------|

|   | · | our ability to accurately forecast the costs required to fully implement new contracts; |
|--------|--------|----------------------------------------------------------------------------------------------|

|   | · | our ability to retain existing customers and to renew or maintain contracts with our customers under existing terms or restructure these contracts on terms that would not have a material negative impact on our results of operations; |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | our ability to accurately forecast performance and the timing of revenue recognition under the terms of our customer contracts ahead of data collection and reconciliation in order to provide forward-looking guidance; |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | the impact of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, “PPACA”), on our operations and/or the demand for our services; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | the impact of any new or proposed legislation, regulations and interpretations relating to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, including the potential expansion to Phase II for Medicare Health Support programs and any legislative or regulatory changes with respect to Medicare Advantage; |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | our ability to anticipate the rate of market acceptance of our solutions in potential international markets; |
|--------|--------|--------------------------------------------------------------------------------------------------------------|

|   | · | our ability to accurately forecast the costs necessary to implement our strategy of establishing a presence in international markets; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------|

|   | · | the risks associated with foreign currency exchange rate fluctuations and our ability to hedge against such fluctuations; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------|

|   | · | the risks associated with deriving a significant concentration of our revenues from a limited number of customers; |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------|

|   | · | our ability to achieve the contractually required cost savings and clinical outcomes improvements and reach mutual agreement with customers with respect to cost savings, or to achieve such savings and improvements within the time frames contemplated by us; |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | our ability to achieve estimated annualized revenue in backlog in the manner and within the timeframe we expect, which is based on certain estimates regarding the implementation of our services; |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | our ability and/or the ability of our customers to enroll participants and to estimate their level of enrollment and participation in our programs in a manner and within the timeframe anticipated by us; |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | the ability of our customers to provide timely and accurate data that is essential to the operation and measurement of our performance under the terms of our contracts; |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | our ability to favorably resolve contract billing and interpretation issues with our customers; |
|--------|--------|-----------------------------------------------------------------------------------------------------------|

|   | · | our ability to service our debt and make principal and interest payments as those payments become due; |
|--------|--------|--------------------------------------------------------------------------------------------------------|

|   | · | the risks associated with changes in macroeconomic conditions, which may reduce the demand and/or the timing of purchases for our services from customers or potential customers, reduce the number of covered lives of our existing customers, or restrict our ability to obtain additional financing; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | counterparty risk associated with our interest rate swap agreements and foreign currency exchange contracts; |
|--------|--------|--------------------------------------------------------------------------------------------------------------|

|   | · | our ability to integrate acquired businesses or technologies into our business and to accurately forecast the related costs; |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------|

|   | · | our ability to anticipate strategic changes and opportunities in our industry and/or business and to accurately forecast the related impact on our earnings; |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | the impact of any impairment of our goodwill or other intangible assets; |
|--------|--------|--------------------------------------------------------------------------|

|   | · | our ability to develop new products and deliver outcomes on those products; |
|--------|--------|-----------------------------------------------------------------------------|

|   | · | our ability to implement our new integrated data and technology solutions platform within the required timeframe and expected cost estimates and to develop and enhance this platform and/or other technologies to meet evolving customer and market needs; |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | our ability to obtain adequate financing to provide the capital that may be necessary to support our operations and to support or guarantee our performance under new contracts; |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | unusual and unforeseen patterns of healthcare utilization by individuals with diseases or conditions for which we provide services; |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------|

|   | · | the ability of our customers to maintain the number of covered lives enrolled in the plans during the terms of our agreements; |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------|

|   | · | the impact of legal proceedings involving us and/or our subsidiaries; |
|--------|--------|-----------------------------------------------------------------------|

|   | · | the impact of future state, federal, and international legislation and regulations applicable to our business, including PPACA, on our ability to deliver our services and on the financial health of our customers and their willingness to purchase our services; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | current geopolitical turmoil, the continuing threat of domestic or international terrorism, and the potential emergence of a health pandemic; and |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | other risks detailed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and other filings with the Securities and Exchange Commission. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | adopt or maintain healthy behaviors; |
|--------|--------|--------------------------------------|

|   | · | reduce health-related risk factors; and |
|--------|--------|-----------------------------------------|

|   | · | optimize care for identified health conditions. |
|--------|--------|-------------------------------------------------|

----

----

----

----

|   |                                         |   |   | Three Months Ended |   |   |   |   |   |   |
|--------|----------------------------------------------|--------|--------|--------------------|--------|--------|--------|--------|--------|--------|
|   |                                         |   |   | March 31,          |   |   |   |   |   |   |
|   |                                         |   |   | 2011               |   | 2010   |   |   |   |   |
|   |                                         |   |   |               |   |   |   |   |   |   |
|   | Revenues                                     |   |   | 100.0              | %      | 100.0  | %      |   |   |   |
|   | Cost of services (exclusive of depreciation  |   |   |               |   |   |   |   |   |   |
|   | and amortization included below)             |   |   | 74.8          | %      | 72.0   | %      |   |   |   |
|   | Selling, general and administrative expenses |   |   | 10.9          | %      | 9.6    | %      |   |   |   |
|   | Depreciation and amortization                |   |   | 7.6           | %      | 7.6    | %      |   |   |   |
|   | Operating income (1)                         |   |   | 6.6           | %      | 10.8   | %      |   |   |   |
|   |                                         |   |   |               |   |   |   |   |   |   |
|   | Interest expense                             |   |   | 2.1           | %      | 1.9    | %      |   |   |   |
|   |                                         |   |   |               |   |   |   |   |   |   |
|   | Income before income taxes                   |   |   | 4.5           | %      | 8.9    | %      |   |   |   |
|   | Income tax expense                           |   |   | 2.0           | %      | 3.6    | %      |   |   |   |
|   |                                         |   |   |               |   |   |   |   |   |   |
|   | Net income                                   |   |   | 2.5           | %      | 5.3    | %      |   |   |   |

----

| ·   | costs associated with securing and implementing certain significant new and innovative contracts; |
|--------------------|---------------------------------------------------------------------------------------------------|

| ·   | an increased portion of our revenue generated by fitness solutions, which typically have a higher cost of services as a percentage of revenue than our other programs, somewhat offset by efficiencies gained in these solutions through economies of scale and cost management initiatives; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | certain costs that cannot reduced in the same proportion and/or timeframe as the decrease in revenues discussed above; |
|--------------------|------------------------------------------------------------------------------------------------------------------------|

| ·   | an increase in consulting expenses primarily related to implementation of our Embrace platform; and |
|--------------------|-----------------------------------------------------------------------------------------------------|

| ·   | changes in the contract structure of certain incentive-based wellness programs from a utilization model to a PMPM model as well as an increase in the number of members eligible for these programs and their utilization of such programs. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | costs involved in pursuing business in evolving markets such as domestic government, community, and certain international markets; and |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------|

| ·   | certain costs that cannot be reduced in the same proportion and/or timeframe as the decrease in revenues discussed above. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------|

| ·   | a decrease in the level of short-term incentive compensation based on the Company’s year-to-date financial performance against established internal targets for these periods; and |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ·   | cost savings realized from a restructuring of the Company that was largely completed during the fourth quarter of 2010. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------|

| ·   | upcoming start dates for certain significant new contracts; |
|--------------------|-------------------------------------------------------------|

| ·   | the recognition of performance-based revenues and other revenues based on achieving certain deliverables; |
|--------------------|-----------------------------------------------------------------------------------------------------------|

| ·   | a decrease in costs associated with securing and implementing certain significant new and innovative contracts; |
|--------------------|-----------------------------------------------------------------------------------------------------------------|

| ·   | ramping member enrollment on certain contracts throughout the year; and |
|--------------------|-------------------------------------------------------------------------|

| ·   | a decrease in incentive costs related to member utilization of certain incentive-based wellness programs, which tends to be higher earlier in the year. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

| Item 3. | Quantitative and Qualitative Disclosures About Market Risk |   |
|---------|------------------------------------------------------------|--------|

----

| Item 4. | Controls and Procedures |   |
|---------|-------------------------|--------|

----

| Item 1. | Legal Proceedings |   |
|---------|-------------------|--------|

----

| Item 1A. | Risk Factors |   |
|----------|--------------|--------|

----

| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds |   |
|---------|-------------------------------------------------------------|--------|

| Period                |   |   | Total Number of Shares Purchased |   |   |   | Average Price Paid per Share |   |   |   | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1) |          |   |   | Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (1) |   |
|-----------------------|--------|--------|----------------------------------|--------|--------|--------|------------------------------|--------|--------|--------|--------------------------------------------------------------------------------------|---------------|--------|--------|------------------------------------------------------------------------------------------------------|--------|
|                  |   |   |                             |   |   |   |                         |   |   |   |                                                                                 |          |   |   |                                                                                                 |   |   |   |
| January 1 through 31  |   |   | 137,600                          |   |   |   |                         | $11.03 |   |   |                                                                                 |  567,254 |   |   |                                                                                                 |   | $53,987,364 |   |
| February 1 through 28 |   |   | 16,000                           |   |   |   |                         | $11.89 |   |   |                                                                                 | 583,254       |   |   |                                                                                                 |   | $53,797,124 |   |
| March 1 through 31    |   |   | 145,293                          |   |   |   |                         | $14.87 |   |   |                                                                                 | 728,547       |   |   |                                                                                                 |   | $51,636,617 |   |
|                  |   |   |                             |   |   |   |                         |   |   |   |                                                                                 |          |   |   |                                                                                                 |   |   |   |
| Total                 |   |   | 298,893                          |   |   |   |                         |   |   |   |                                                                                 |          |   |   |                                                                                                 |   |   |   |

| Item 3. | Defaults Upon Senior Securities |   |
|---------|---------------------------------|--------|

|   | Not Applicable. |   |
|--------|-----------------|--------|

| Item 4. | Removed and Reserved |   |
|---------|----------------------|--------|

| Item 5. | Other Information |   |
|---------|-------------------|--------|

|   | Not Applicable. |   |
|--------|-----------------|--------|

| Item 6. | Exhibits |   |
|---------|----------|--------|

|   | (a) | Exhibits |
|--------|-----|----------|

|   |   |                                                                                                                                                                 |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.1   |   | Amendment to Employment Agreement dated April 6, 2011 between the Company and Alfred Lumsdaine                                                                       |
|   |   |                                                                                                                                                                 |
| 31.1   |   | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended                                    |
|   |   |                                                                                                                                                                 |
| 31.2   |   | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended                                    |
|   |   |                                                                                                                                                                 |
| 32     |   | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |

----

|   |        |   |   | Healthways, Inc.              |
|--------|-------------|--------|--------|-------------------------------|
|   |        |   |   | (Registrant)                  |
|   |        |   |   |                          |
|   |        |   |   |                          |
|   |        |   |   |                          |
|   |        |   |   |                          |
| Date   | May 9, 2011 |   | By     | /s/ Alfred Lumsdaine          |
|   |        |   |   | Alfred Lumsdaine              |
|   |        |   |   | Chief Financial Officer       |
|   |        |   |   | (Principal Financial Officer) |

----